NICE nod for Amgen’s Parsabiv

7th March 2017 Uncategorised 0

Cost regulators for treatments funded on the NHS in England and Wales are backing use of Amgen’s Parsabiv to treat secondary hyperparathyroidism (sHPT), which could give patients routine access to the first new option to treat the disease in more than a decade.

More: NICE nod for Amgen’s Parsabiv
Source: News